Furthermore, upregulated CD73 protein levels in tumor tissues correlate with adverse clinical prognosis in several tumor types, such as chronic lymphocytic leukemia [14], triple-negative breast cancer [15], urothelial bladder cancer [16], and gliomas [17], which further highlights the vital role of CD73 in tumor development. This evidence concerns the gene NT5E and B-cell chronic lymphocytic leukemia.